Evidence map›Paper›PMID 33681439›Full record

ArticleJAAD case reports2021

Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation.

Girish Gilly Munavalli, Siri Knutsen-Larson, Mary P Lupo, Roy G Geronemus

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JAAD case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 5 pooled it
18.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Adverse Events and Safety of SARS-CoV-2 Vaccines: What's New and What's Next.The journal of allergy and clinical immunology. In practice · 2022
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Girish Gilly MunavalliDermatology, Laser and Vein Specialists of the Carolinas, Charlotte, North Carolina.
Siri Knutsen-LarsonSouth Dakota Sanford School of Medicine, Vermillion, South Dakota.
Mary P LupoLupo Center for Aesthetic and General Dermatology, New Orleans, Louisiana.
Roy G GeronemusLaser and Skin Surgery Center of New York, New York, New York.
Center for Aesthetic Dermatology & Laser Surgery · USDermatology, Laser & Vein Specialists of the Carolinas · USLaser and Skin Surgery Center of New York · USUniversity of South Dakota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ACE2, angiotensin-converting enzyme receptorACE-I, angiotensin-converting enzyme inhibitorAngII, angiotensin IIangiotensin-converting enzyme inhibitorangiotensin IICOVID-19delayed inflammatory reactiondelayed inflammatory reaction (DIR)dermal fillerDIR, delayed inflammatory reactionedemahyaluronic acidmRNA, messenger RNARAS, renin-angiotensin systemSARS-CoV-2

Identifiers

PMID33681439
PMCPMC7923909
OpenAlexW3134265861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.